Cool Daniel, Coventon James, Sharma Abhishek
Ophthalmology Department, Princess Alexandra Hospital, Brisbane, Queensland, Australia.
Ophthalmology Department, Cairns Hospital, Cairns, Queensland, Australia.
Case Rep Ophthalmol Med. 2024 Dec 10;2024:5834769. doi: 10.1155/crop/5834769. eCollection 2024.
To describe a case of regression of proliferative diabetic retinopathy (PDR) following treatment with semaglutide. Case report. The case describes a 47-year-old woman with Type 2 diabetes, obesity, hypertension, and dyslipidaemia who had difficulty controlling her blood sugar levels despite oral hypoglycaemic medications. She presented with PDR in her right eye and severe nonproliferative diabetic retinopathy (NPDR) in her left eye. After missing her follow-up appointment for panretinal photocoagulation (PRP), her general practitioner initiated semaglutide therapy. Despite minimal changes in glycaemic control, the patient exhibited resolution of neovascularisation in her right eye and improved diabetic macular oedema (DMO) within 6 weeks of semaglutide therapy. This case report suggests a potential independent role for semaglutide in managing PDR.
描述一例司美格鲁肽治疗后增殖性糖尿病视网膜病变(PDR)消退的病例。病例报告。该病例为一名47岁女性,患有2型糖尿病、肥胖症、高血压和血脂异常,尽管服用了口服降糖药,但血糖水平仍难以控制。她右眼患有PDR,左眼患有严重非增殖性糖尿病视网膜病变(NPDR)。在错过全视网膜光凝(PRP)的随访预约后,她的全科医生开始了司美格鲁肽治疗。尽管血糖控制变化甚微,但在司美格鲁肽治疗6周内,患者右眼新生血管消退,糖尿病性黄斑水肿(DMO)改善。本病例报告提示司美格鲁肽在治疗PDR方面可能具有独立作用。